This inventor holds 2 USPTO granted patents. Top assignee: Hangzhou Adcoris Biopharma Co., Ltd.. Active years: 2023-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023-2025
Title: Sheldon Cao: Innovator in Antibody-Drug Conjugates
Introduction
Sheldon Cao is a prominent inventor based in Zhejiang, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of antibody-drug conjugates. With a total of 2 patents, his work focuses on innovative solutions for cancer treatment.
Latest Patents
Cao's latest patents include the "Anti-HER2 antibody-drug conjugate and application thereof." This invention involves an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate, which is designed for preparing an antitumor pharmaceutical product. Another notable patent is the "Anti-5T4 antibody-drug conjugate and use thereof." This invention provides an anti-5T4 antibody-drug conjugate and outlines its pharmaceutical use in inhibiting or preventing tumors.
Career Highlights
Sheldon Cao is currently associated with Hangzhou Adcoris Biopharma Co., Ltd. His work at this company has positioned him as a key player in the biopharmaceutical industry. His innovative approaches to drug development have garnered attention and respect within the scientific community.
Collaborations
Cao collaborates with talented individuals such as Zhenwei Miao and Tong Zhu. These partnerships enhance the research and development efforts at Hangzhou Adcoris Biopharma Co., Ltd.
Conclusion
Sheldon Cao's contributions to the field of biopharmaceuticals through his patents and collaborations highlight his role as an innovator. His work continues to pave the way for advancements in cancer treatment.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile